Here's Why You Should Add Cabot Stock to Your Portfolio Now
CBT's battery materials expansion, upbeat earnings outlook, strong cash generation and cost-cutting initiatives position it for sustained long-term growth.
Are Investors Undervaluing Cabot (CBT) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Cabot (CBT) Outperforming Other Basic Materials Stocks This Year?
Here is how Cabot (CBT) and Carpenter Technology (CRS) have performed compared to their sector so far this year.
Cabot Expands Battery Materials Platform With $50M DOE Grant
CBT plans a two-site battery materials expansion, backed by a modified $50M DOE grant, to boost U.S. conductive additives output by 2028.
Cabot Stock Rallies 17% in 6 Months: Here's What's Driving the Upside
CBT shares climb 16.8% in six months as Battery Materials demand, capacity expansion and cost savings support growth and cash generation.
Why Is Cabot (CBT) Down 1.6% Since Last Earnings Report?
Cabot (CBT) reported earnings 30 days ago. What's next for the stock?
Reasons Why You Should Retain Cabot Stock in Your Portfolio Now
CBT is riding battery-materials growth, circular products and capacity expansion, even as weaker pricing and rising costs pressure profitability.
CBT Q3 Earnings Beat Estimates on Performance Chemicals Strength
Cabot's Q3 fiscal 2026 earnings beat estimates as Performance Chemicals gains offset Reinforcement Materials margin pressure.
Cabot Q3 Earnings Call Highlights
Cabot NYSE: CBT reported third-quarter fiscal 2026 adjusted earnings per share of $1.67, up 4% sequentially, as strength in its Performance Chemicals segment helped offset lower earnings in Reinforcement Materials.
Cabot Corporation: Successful Returns, Downgrading Into 2027-2028E (Downgrade)
Cabot Corporation is now fairly valued after a period of significant undervaluation and strong operational outperformance. I downgrade CBT to Hold with a new price target of $82/share, as the current upside is limited following a 20-30% rally. CBT's disciplined capital allocation, low leverage, and resilient margins underpin its stability despite cyclical end-market pressures.
Cabot (CBT) Tops Q3 Earnings and Revenue Estimates
Cabot (CBT) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.9 per share a year ago.
All You Need to Know About Cabot (CBT) Rating Upgrade to Buy
Cabot (CBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
